( EuronextBrussels:UCB,OTC-PINK:UCBJY )

News from ucb, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 21, 2015, 07:00 ET UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

 UCB today announced regulatory milestones in the US and the EU for its investigational antiepileptic drug brivaracetam. In the US, the Food...


Nov 14, 2014, 01:00 ET UCB shows strong scientific presence at leading rheumatology meeting

UCB, a global biopharmaceutical company, is sponsoring 27 data presentations at the American College of Rheumatology/Association of...


Oct 22, 2014, 12:00 ET UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at American College of Gastroenterology 2014 Annual Scientific Meeting

 UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring several data presentations on...


Nov 20, 2013, 07:00 ET New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society

  UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, will be sponsoring 15 data presentations at...


Nov 04, 2013, 07:00 ET UCB files VIMPAT® (lacosamide) in the US as monotherapy treatment in adult epilepsy patients with partial-onset seizures

 UCB announced that the US Food and Drug Administration (FDA) has accepted for filing a supplemental new drug application (sNDA) for...


Oct 25, 2013, 07:00 ET UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at 2013 American College of Rheumatology Annual Scientific Meeting

 UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring multiple data presentations on...


Oct 18, 2013, 07:00 ET Cimzia® (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis

regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab...


Oct 03, 2013, 11:30 ET UCB highlights educational support programs for people living with Parkinson's disease at the World Parkinson Congress

 UCB today announced two poster presentations at the 2013 World Parkinson Congress (WPC) highlighting key Parkinson's disease (PD) patient...


Sep 30, 2013, 07:00 ET Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis

 regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia®...


Aug 29, 2013, 12:41 ET NEUPRO® (rotigotine) Now Available in Canada to Treat Parkinson's Disease

TORONTO, Aug. 29, 2013 /CNW/ - UCB Canada Inc. announced today that NEUPRO® (rotigotine) is now available in Canada for the treatment of...


Jun 18, 2013, 09:07 ET Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy

 regulated information — Global biopharmaceutical company UCB, Inc. and professional golfer Jeff Klauk today announced the launch of a...


Apr 02, 2013, 08:04 ET Health Canada approves NEUPRO® (rotigotine) patch for treatment of Parkinson's disease and Restless Legs Syndrome

Novel dosage form represents new treatment for Parkinson's with efficacy in motor symptoms of the disease OAKVILLE, ON, April 2, 2013 /CNW/ -...


Mar 26, 2013, 13:12 ET New resource promises information, education and inspiration when it comes to epilepsy in Canada

E-Action™ designed for the 300,000 living with the neurological disorder1 OAKVILLE, ON, March 26, 2013 /CNW/ - Canadians with epilepsy, as...


May 18, 2012, 10:00 ET UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012

UCB, Inc., a leading biopharmaceutical company dedicated to the research and development of treatments for severe central nervous system and...


Apr 20, 2012, 13:00 ET New Neupro® Data in Parkinson's Disease and Restless Legs Syndrome to be Presented at the 64th American Academy of Neurology Annual Meeting

 Data examining the effect of Neupro® (rotigotine transdermal system) in both Parkinson's disease and Restless Legs Syndrome (RLS) will...


Jan 13, 2012, 10:30 ET HealthyWomen and UCB, Inc. Host "Women Succeeding with Chronic Conditions" Health Pavilion at NBC4 Health and Fitness Expo

 Millions of people in the U.S. live with chronic health conditions, and many may find it difficult to manage their condition. The Women...


Dec 05, 2011, 12:30 ET Long-term Use of Antiepileptic Drug Vimpat® (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures

 UCB today announced new findings for Vimpat® (lacosamide) C-V that offer additional support regarding the long-term...


Nov 30, 2011, 12:30 ET New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society

UCB, a leading biopharmaceutical company committed to the development of new epilepsy treatments and research, is proud to sponsor several...


Nov 30, 2011, 10:00 ET 2011 UCB Crohn's and Me Scholarship™ Winners Announced

UCB, Inc., a leading biopharmaceutical company at the forefront of immunology treatments and research, announced the 30 recipients of the 2011 UCB...


Nov 30, 2011, 10:00 ET 2011 UCB Rheumatoid Arthritis Family Scholarship™ Winners Announced

 UCB, Inc., a leading biopharmaceutical company focused on immunology treatments and research, today announced the 30 recipients of...


Nov 17, 2011, 10:00 ET UCB Family Epilepsy Scholarship™ Announces 2011 Recipients

UCB, Inc. today announced 40 recipients of the 2011 UCB Family Epilepsy Scholarship, recognizing outstanding individuals from across the country...


Jun 09, 2011, 12:16 ET UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities

UCB, Inc. today announced an agreement with the U.S. Department of Justice (DOJ) to resolve a previously disclosed government investigation into...


Jun 01, 2009, 09:08 ET Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

Cimzia(R) shows duration of response up to week 26 in moderate to severe Crohn's patients who failed the intravenous infusion treatment...


Jun 01, 2009, 09:07 ET UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows

UCB, Inc. and the Crohn's Disease Working Group (CDWG) today announced the four recipients of the 2009 Research Awards in Inflammatory Bowel...


Dec 03, 2007, 00:00 ET UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients

ATLANTA, Dec. 3 /PRNewswire/ -- UCB today announced new data demonstrating that the investigational drug lacosamide, with the proposed brand...